Braden Michael Leonard

October 9, 2026

Hims & Hers news mentioned in broader market context. Recent coverage from Yahoo discusses reasons to retain Hims & Hers stock, which shares the digital health sector with Outset Medical. While the article focuses on a different company, it highlights ongoing investor interest in the broader telehealth and digital medicine space. Outset Medical remains a high-beta stock with significant volatility, as seen in its wide 52-week range.

October 16, 2026

ACRS Not Highlighted in Recent Pre‑Market Moves. In the past week, pre‑market activity focused on large financial names and a list of 20 stocks, but Aclaris Therapeutics was not mentioned. The moves in big banks and other sectors could influence overall market sentiment, which may affect smaller biotech names like ACRS. No direct company news was reported, so the impact is limited at this time.

October 1, 2026

Astrotech Reports FY2026 Results With Widening Losses. Astrotech released its fiscal year 2026 financial results, reporting a quarterly loss of $1.83 per share, which widened from $1.75 in the same period last year. Revenue also declined to $126,000, down from $220,000 in the prior year. These figures highlight continued financial pressure for the company as it navigates its current operational challenges.

September 27, 2026

AN2 Therapeutics: Failed Drug Potential Value Driver. Seeking Alpha reports that a previously failed drug from AN2 Therapeutics may become a significant value driver for the company. This development is relevant as it suggests potential new revenue or licensing opportunities. The stock is currently trading near its support level, with an average analyst target of $9.00.

September 30, 2026

TECX Reports Positive Phase 1 Data for TX2100 in HHT. Tectonic Therapeutic released results from its Phase 1 study of TX2100, a treatment aimed at hereditary hemorrhagic telangiectasia. The data showed the drug was safe, well tolerated and demonstrated expected pharmacokinetic behavior. These early findings support continued development of the candidate. The news arrives while the stock is trading near a long‑term support level.

October 11, 2026

Enliven's ENABLE-2 Trial Design Sparks New Questions. Enliven Therapeutics has clarified the design of its ENABLE-2 Phase 3 trial for relcobatinib in chronic myeloid leukemia, following questions raised by the trial’s structure. The company also confirmed FDA alignment on the study, while a separate patent dispute involving Halozyme and Merck has kept the leukemia treatment landscape in focus. These developments highlight the regulatory and strategic challenges Enliven faces as it moves toward clinical milestones.

October 1, 2026

RVP Announces Dividends for Series II & III Preferred Shares. Retractable Technologies reported that it will pay dividends to holders of its Series II and III Class B preferred stock. The announcement provides a cash return to preferred shareholders and may affect the stock’s yield expectations. The dividend declaration comes as the common shares trade near the middle of their 52‑week range.

October 13, 2026

Disc Medicine faces valuation scrutiny and whale activity. Recent commentary questions whether Disc Medicine's stock price fully reflects its market position relative to competitors. Additionally, the stock appeared on a list of healthcare names showing significant large-scale trading activity. The stock is currently trading near its 52-week low, which provides context for these recent market observations.